Week In Review: US FDA Rejects Innovent/Lilly PD-1 NDA Based On China-Only Trial Subjects
February 12, 2022 at 15:00 PM EST
A US FDA oncology advisory panel rejected the NDA submitted by Innovent and Lilly for their partnered anti-PD-1 antibody. Lilly tried to influence the panel by announcing it would offer the drug at a wholesale price 40% lower than the competition.
